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In 2001 in Germany, Cumpylobacter was second to Salmonella as the most frequent foodborne pathogen isolated 
from humans. This is also true for the major part of the European population with incidence data available, namely 
Germany, Hungary, Belgium, Denmark, Austria and Spain, with a total population of 154.5 million, and incidence 
rates for Salmonella and Campylobacter of 81.8/100 000 and 49.0/100 000 respectively. Countries where Campylobacter 
is predominant are the UK, Switzerland, Sweden, Finland, Norway, and The Netherlands, with a total population of 
94.2 million, and incidence rates for Campylobacter and Salmonella of 79.61100 000 and 33.31100 000, respectively. 
Shigella is rarely isolated in Europe (1.9-45100 000). Epidemiologic risk factors for human campylobacteriosis are 
poultry, untreated milk, and surface water. Travel plays an important role, especially in Scandinavia and the UK. 
Isolates acquired outside these countries are much more often resistant to fluoroquinolones than are domestic strains. 
Fluoroquinolone resistance in human Campylobacter isolates is lowest in the UK and Denmark, at 12%. Resistance 
quotesof around 2040% are found in Finland, The Netherlands, Norway, Sweden, Austria, and Germany, and peaks 
in Spain reaching 70-80%. Usually, uncomplicated Cumpylobacter enteritis is symptomatically treated. If, in severe 
cases, antimicrobials are indicated, in all European countries except Switzerland, macrolides are used as first-line 
drugs, followed by fluoroquinolones or doxycycline. 
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INCIDENCE RATES OF CAMPYLOBACTERIOSIS 
AND SALMONELLOSIS IN CENTRAL AND 
WESTERN EUROPE 
In Germany, where campylobacteriosis is a reportable 
disease, the number of cases reached 54 410 (66.2/ 
100 000) in 2OOl.l This was the second commonest cause 
of bacterial diarrhea behind salmonellosis, of which 
77 186 (93.9/100 000) cases were reported. Other 
reported enteric infections, in order of decreasing 
frequency, were rotavirus infections (47 481) Norwalk- 
like virus infections (9217) yersiniosis (7186) shigellosis 
(1617) and infections caused by enterohemorrhagic 
Escherichia coli (1007).’ Additional European countries 
with salmonellosis predominating among foodborne 
infections were, as reported in 1998, Belgium, Austria, 
Denmark, and Spain, and probably Hungary, with a very 
high annual incidence rate of 179.3/100 000 inhabitants 
(Table 1).2 In the latter case, data for campylobacteriosis 
were not available. Interestingly, all countries with 
Salmonella as a leading foodborne pathogen are pre- 
dominantly located in central Europe. This ‘salmon- 
ellosis island’ is surrounded, especially in the northern 
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part, by countries with campylobacteriosis as the most 
frequently reported bacterial foodborne infection, 
namely England/Wales, with the highest incidence (103.7/ 
100 000), followed by Switzerland, Sweden, Finland, 
Norway and The Netherlands (Table 2).* Data on the 
frequency of human campylobacteriosis from two 
further important countries, namely Italy and France, 
are not available. 
If European incidence data are compared with the 
US FoodNet data,3 and if shigellosis is included in the 
Table 1. Cases of notifiable foodborne infections in countries 
with predominance of salmonellosis (incidence per 100000 
inhabitants)‘,* 
Country Year Salmonellosis 
Hungary 1998 18 107 (179.3) 
Belgium 1998 13 853 (137.2) 
Germany 2001 77 186 (93.9) 
Austria 1998 7 236 (89.3) 
Denmark 1998 3 802 (72.1) 
Spain 1998 6 653 (16.9) 
Campylobacteriosis 
No data 
6 610 (65.4) 
54 410 (66.2) 
2 454 (30.3) 
3 372 (64.0) 
4 389 (11.1) 
Table 2. Cases of notifiable foodborne infections in countries 
with predominance of campylobacteriosis (incidence per 
100000 inhabitants)2 
Country Year Campylobacteriosis Salmonellosis 
EnglandMales 1999 54 987 (103.7) 17 532 (33.1) 
Switzerland 1998 5 455 (76.5) 3 004 (42.1) 
Sweden 1998 6 543 (73.9) 4 308 (48.6) 
Finland 1998 2 851 (55.9) 2 742 (53.8) 
Norway 1998 1706 (39.5) 1 494 (34.7) 
The Netherlands 1998 3 398 (21.5) 2 266 (14.2) 
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Figure 1. Incidence rates and relative impact (%) of campylo- 
bacteriosis, salmonellosis and shigellosis in European countries 
and the USA. 
comparison (Figure l), it is clearly apparent that in 
the USA, the total incidence rates for salmonellosis 
(14.4/100 000) and campylobacteriosis (15.71100 000) 
are substantially lower than in Europe. The impact of 
shigellosis (7.9000 000), on the other hand, seems to be 
much higher in the USA than in European countries 
(1.9-4.5/100 000). From the above, we can see that 
salmonellosis is still predominant in the major parts of 
Europe, and shigellosis is rare. In contrast, shigellosis is 
much more frequently reported in the USA, but the 
incidence rates for both salmonellosis and campylo- 
bacteriosis are comparably low and do not differ signifi- 
cantly. 
SOURCES AND ROUTES OF TRANSMISSION 
OF EUROPEAN CAMPYLOBACTERIOSIS 
Epidemiologic risk factors for human campylobacteriosis 
do not apparently vary between Europe and the USA. 
As shown by case-control studies, consumption of poultry 
and unpasteurized milk, and contact with untreated sur- 
Table 3. Clinical management of enteritis in European countries 
face water, are the main sources.4-y Most human cases 
are sporadic; only a few outbreaks have been reported, 
and these were related to milk or untreated drinking 
water consumption. lo-l4 A further significant source of 
cases is travel, especially to southern Europe, Africa, 
and Asia. Imported cases have a substantial impact, 
especially in the Scandinavian countries and the 
UK.G8, 15-17 In some of these countries, almost two- 
thirds of cases are imported.18,1y This is of particular 
relevance for the choice of the first-line antimicrobial 
treatment drug, because resistance, especially against 
fluoroquinolones, is significantly higher in such strains, 
predominantly in those imported from South-East Asia 
or Spain.1y-21 
CLINICAL FEATURES 
Enteritis is the most common illness associated with 
Campylobacter infection. Frequently, a prodromal period 
lasting from a few hours to a few days, and characterized 
by headache, back pain, myalgia, and low fever, precedes 
the acute phase of the disease, which often starts with 
severe abdominal cramps, followed by up to 20 watery 
bowel movements per 24 h, leading, in a high number 
of cases, to gross bloody diarrhea. The onset of acute 
diarrhea is often accompanied by high fever, peaking 
during the first 2 days of illness. The presence of blood in 
stools is frequently observed in Campylobacter enteritis.22 
Vomiting is not a typical symptom. Diarrhea was seen in 
95% of 499 cases prospectively investigated from 1980 to 
1985 in a total of about 17 000 patients suffering from 
diarrhea in the southwest of Germany. In 37%, gross 
blood was visible. The other main symptoms were lower 
abdominal cramps (84%), headache (53%), and fever of 
39°C and higher (53%). Septicemia was observed in three 
of 499 cases, and development of Guillain-Barre syn- 
drome in three of 946 cases, respectively. In the vast 
majority of the cases, the disease was self-limiting, with a 
mean duration of illness of 7 days. Eighty per cent of the 
reported cases, especially adults, did not need hospital 
care.23 
Country 
Uncomplicated 
enteritis 
Severe cases, 
first line 
Severe cases, 
second line 
UK Symptomatic 
Germany Symptomatic 
Denmark Symptomatic 
The Netherlands Symptomatic 
France 
Sweden 
Austria 
Finland 
Belgium 
Symptomatic 
Symptomatic 
Symptomatic 
Symptomatic 
Symptomatic 
Switzerland Symptomatic or FQ 
Erythromycin 
Erythromycin 
Erythromycin 
Erythromycin 
Macrolides 
Macrolides 
Macrolides 
Macrolides 
Macrolides 
FO 
FQ 
FQ 
FQ 
FQ 
FQ 
Doxycycline 
No data 
No data 
No quinolone 
Macrolides 
FQ, fluoroquinolone. 
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EUROPEAN MANAGEMENT STRATEGIES in infants and children and are reserved for severe in- 
FOR HUMAN CAMPYLOBACTERIOSIS fections. 
TO obtain more recent information regarding European 
treatment strategies for human campylobacteriosis, a 
questionnaire was distributed in 12 countries by E-mail, 
asking for the recommended first- and second-line 
treatment regimens for enteric infections caused by 
Campylobacter jejurdcoli. The questionnaires were sent, 
whenever available, to the National Scientific Societies 
of Infectology, or local international recognized experts 
in the field of Campylobacter infections. National guide- 
lines on antimicrobial treatment regimens were used 
whenever available. Information from one or more 
sources was provided from a total of 11 European coun- 
tries. As shown in Table 3, all recommended treatment 
regimens differentiated between ‘uncomplicated enteritis’ 
and ‘severe cases’. With one exception, in all countries 
from which information was available, symptomatic treat- 
ment (non-antibiotic) of uncomplicated enteritis was 
recommended. All countries, with one exception, 
recommend macrolides, preferably erythromycin, as 
the first-line drugs in severe cases. Fluoroquinolones 
were typically used as second-line drugs. In Sweden 
and Belgium, fluoroquinolones are not recommended 
for treatment of campylobacteriosis. In both these coun- 
tries, fluoroquinolones are not recommended because of 
presumed high rates of resistance against these drugs. 
A further reason is the possibility that strains could 
become quinolone resistant during antimicrobial treat- 
ment, a phenomenon which was observed in some 
earlier studies.24-29 
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PANEL DISCUSSION 
0. Radostits: One thing that struck me was that the rate 
of Cumpylobacter infection in Europe seems dramatically 
higher than the reported rate in the USA. Do you think 
that this represents a real phenomenon, or merely a 
greater tendency to identify the pathogens? 
M. Kist: I think that the system of reporting bacterial 
agents is a rather good development in Europe, and that 
this low incidence in the USA may be due to the fact 
that in the USA the FoodNet has cases reported only 
from some states. If you examine the data from recent 
years, you can see some variation in the impact of the 
different agents, and I think that this was sometimes 
because new areas were included in the surveillance 
system. 
D. Meeker: Was I reading that slide correctly, in that 
there was a 75% resistance rate among Salmonella to 
fluoroquinolones in Spain? 
M. Kist: No, this referred to resistance rates among 
Campylobacter. 
D. Meeker: Why is there more Shigella in the USA? 
M. Kist: This may be because, in the USA, shigellosis is 
most frequently found in the mid-west and in the areas 
of Native American reservations, where it is very fre- 
quent. I don’t know the reason for this. One possibility 
is that transmission between small infants in kinder- 
garten occurs more frequently in the USA than in 
Germany. 
M. Pasternack: It may have something to do with the 
fact that most of the shigellosis that we see is institu- 
tional. The incidence has risen and fallen a lot because, 
in the last year or so, there has been a huge outbreak 
in the mid-west around Cincinnati in schoolchildren. 
Therefore, I think that a combination of schools and 
institutions is responsible. 
M. Kist: I agree, but I can only report for Germany; 
travel abroad from Germany leads to a 30 times higher 
chance of getting shigellosis. 
C. Thornsberry: Another interesting and important 
point that should probably have been mentioned is that, 
in this country, shigellosis is much more resistant to 
antibiotics than any of the other organisms that we have 
discussed. 
L. Vogel: Having heard several talks on the risk factors, 
it strikes me as curious that, wherever you go, foreign 
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travel is a risk factor. It would seem to me that there 
ought to be some place that is worse off than you are, 
and that if you went there, it would be protective. I 
wonder if the important factor is going to a foreign place 
with more enteric organisms, or going to a place with 
different organisms. This is interesting, because when 
you throw groups of populations together, you get a lot 
of disease because everybody trades microbes. This has 
been shown in the military, and there is a great deal of 
literature concerning people who have diverse floras 
that don’t interact well together. 
M. Kist: What we observed in Germany is that most 
imported cases of campylobacteriosis came from Spain, 
from Central Africa, and from Nepal and India. 
S. Pretanik: You mentioned the high resistance rates of 
fluoroquinolones in several European countries. Does 
this apply to nalidixic acid, all quinolones, or a specific 
quinolone? 
M. Kist: It was difficult to demonstrate all these data in 
detail. Some countries obtained their data by testing 
nalidixic acid resistance, and others by testing quinolone 
resistance. We discussed this 2 weeks ago in Berlin. 
Nalidixic acid resistance is, as we all know, a step towards 
the development of resistance against fluoroquinolones, 
so the figures are probably higher. I think that Diane 
probably has the same opinion that, comparing nalidixic 
acid and fluoroquinolone resistance, if there are 100 
strains resistant to nalidixic acid, there would be 80 
resistant to fluoroquinolones 
